BT

Biotricity IncNASDAQ BTCY Stock Report

Last reporting period 31 Mar, 2024

Updated 24 Oct, 2024

Last price

Market cap $B

0.006

Micro

Exchange

XNAS - Nasdaq

BTCY Stock Analysis

BT

Uncovered

Biotricity Inc is uncovered by Eyestock quantitative analysis.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

-42/100

Low score

Market cap $B

0.006

Dividend yield

Shares outstanding

52.515 B

Biotricity, Inc. is a medical technology company, which is focused on biometric data monitoring solutions. The company is headquartered in Redwood City, California and currently employs 44 full-time employees. The company went IPO on 2015-10-26. The firm is focused on biometric data monitoring solutions. The firm developed its Bioflux MCT technology, comprised of a monitoring device and an ECG reporting software component. The Bioflux device is comprised of a wet electrode and worn on a belt clip around the waist. The Bioflux ECG reporting software enables doctors and labs to view a patient’s electrocardiogram (ECG) data for monitoring and diagnostic purposes. Both the device and software are in accordance with mobile cardiac telemetry (MCT) billing code standards, compliant with arrhythmia devices and alarms, and require 510000 clearance, which has been obtained. The Bioflux device has been developed, among other things, with global system for mobile communications (GSM) mobile chip for global cellular network compatibility; touch-screen liquid crystal display (LCD) viewer; and extended battery pack for an additional approximately 48 hours of battery life.

View Section: Eyestock Rating